Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of July 2026 for Nasus Pharma Ltd., a foreign private issuer headquartered in Tel Aviv, Israel. The report primarily addresses significant changes in executive leadership and corporate governance rather than financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or operational metrics.
Material Changes
- CEO Appointment: On July 27, 2026, the Company appointed Mr. Brendan P. O'Grady as Chief Executive Officer, effective immediately. Mr. O'Grady brings extensive experience from Assertio Holdings, Glenmark Pharmaceuticals, American Well, Teva Pharmaceutical, and Sanofi.
- CEO Departure: Mr. Dan Teleman resigned as CEO and from the Board of Directors, effective July 22, 2026, pursuant to a mutual separation agreement. His resignation was not related to any disagreement regarding operations, policies, or practices.
- Board Composition: Mr. O'Grady was appointed to the Board of Directors to fill the vacancy left by Mr. Teleman, serving as a Class III director until the 2028 annual general meeting.
Outlook, Risks, and Management Commentary
Management indicated that Mr. O'Grady's appointment is intended to lead strategic growth. Mr. Teleman will remain employed through the expiration of his contractual notice period to assist with the transition but will not perform day-to-day responsibilities. Mr. O'Grady's compensation package has been approved by the Board but remains subject to shareholder approval. The Company issued an updated corporate presentation on July 28, 2026.
Key Facts for Investor Verification
- Verify the terms of Mr. O'Grady's employment agreement and the specific details of his compensation package pending shareholder approval.
- Confirm the status of the transition plan between Mr. Teleman and Mr. O'Grady.
- Review the updated corporate presentation (Exhibit 99.2) for strategic updates not detailed in the text of this filing.
- Note that no financial data is included in this specific filing; investors should refer to the most recent Form 20-F for financial metrics.